NovoLog


Also found in: Medical, Wikipedia.

No·vo·Log

 (nō′vō-lôg′, -lŏg′, -və-)
A trademark for the drug insulin aspart.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Drugs like Sanofi 's Lantus, Merck's Janumet , Januvia, Eli Lily Co's Humalin, Humalog, Novo Nordisk's Novorapid, Novolog, Levemir, and Victoza and Novartis' Galvus are popular in Diabetes treatments.
"With the introduction of the more-rapid-acting insulins, like aspart, Humalog and NovoLog, the difference is not [in] any efficacy at all," Rushakoff told Live Science.
Humalog and NovoLog have been tested by Valeritas, Inc.
Those patients also pay an average $632 for a monthly supply of NovoLog FlexPen, another insulin brand, compared with $28 in Australia, $42 in the United Kingdom and $47 in Canada.
His home insulin regimen included 10 units of NovoLog three times a day with meals and Lantus 20 units every morning.
Fiasp is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes.
The company stated Fiasp is a new formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in about two and half minutes.
Among those expiring in 2017 are Avandia, Evista, Rhinoccort, Prozac Weekly, Sequel SR, Novolog, Biaxin XL, Victoza, Effexor SR and Ventolin HFA.
Onset, h Peak, h Duration, h Rapid-acting analogs Insulin lispro (Humalog) <0.25-0.5 0.5-2.5 3-5 Insulin aspart (Novolog) <0.25 1-3 3-5 Insulin glulisine (Apidra) <0.25 0.75-2 3-5 Short-acting Regular insulin, CZI, 0.5-1 2-3 5-8 soluble Intermediate-acting NPH, isophane 2-4 4-10 10-16 Long-acting analogs Insulin glargine (Lantus) 2 Relatively 11-24 flat Insulin detemir (Levemir) 1-2 Relatively Dose dependent flat 12 h for 0.2 U/kg 14 h for 0.4 U/kg range 7.6-24 h
This collaboration grants Mylan with the rights to develop and market Biocon's Glargine (the generic version of Sanofi's Lantus), Lispro (the generic version of Eli Lilly and Company's Humalog) and Aspart (the generic version of Novo Nordisk's NovoLog).